10.08.2012 Views

talanx group annual report 2011 en

talanx group annual report 2011 en

talanx group annual report 2011 en

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

140<br />

Financial statem<strong>en</strong>ts Notes<br />

G<strong>en</strong>eral information<br />

Talanx Group. Annual Report <strong>2011</strong><br />

Accounting principles<br />

and policies<br />

Segm<strong>en</strong>t <strong>report</strong>ing Consolidation,<br />

business combinations<br />

Non-curr<strong>en</strong>t assets held for<br />

sale and disposal <strong>group</strong>s<br />

Technical provisions: As at 31 December <strong>2011</strong>, the Group recognised loss and loss adjustm<strong>en</strong>t<br />

exp<strong>en</strong>se reserves in the amount of EUR 31,420 million and b<strong>en</strong>efit reserves in the amount of<br />

EUR 45,739 million. The loss and loss adjustm<strong>en</strong>t exp<strong>en</strong>se reserves, the amount and maturity of<br />

which are uncertain, are recognised according to “best estimate” principles in the amount that will<br />

probably be utilised. The actual amounts payable may prove to be higher or lower; any resulting<br />

run-off profits or losses are recognised in income. In the area of life insurance and life/health reinsurance,<br />

the determination of provisions and assets is crucially dep<strong>en</strong>d<strong>en</strong>t on actuarial projections<br />

of the business. In this context key input parameters are either predetermined by the metrics of the<br />

insurance plan (e.g. costs included in the calculation, amount of premium, actuarial interest rate)<br />

or estimated (e.g. mortality, morbidity or lapse rates). These assumptions are heavily dep<strong>en</strong>d<strong>en</strong>t, for<br />

instance, on country-specific parameters, sales channel, quality of underwriting and type of reinsurance.<br />

For the purposes of US GAAP accounting these assumptions are reviewed as at each balance<br />

sheet date and subsequ<strong>en</strong>tly adjusted in line with the actual projection. The resulting effects are<br />

reflected, for instance, in true-up adjustm<strong>en</strong>ts in the balance sheet items “Other intangible assets,”<br />

“Insurance-related intangible assets (PVFP),” “Deferred acquisition costs,” “Provision for premium<br />

refunds” (provision for deferred premium refunds) and, where applicable, the “B<strong>en</strong>efit reserve”<br />

(funding of maturity bonuses).<br />

Fair value or impairm<strong>en</strong>ts of financial instrum<strong>en</strong>ts: Financial instrum<strong>en</strong>ts with a fair value of<br />

EUR 37,203 million were recognised at the balance sheet date. Fair values and impairm<strong>en</strong>ts for<br />

financial instrum<strong>en</strong>ts, especially for those not traded on an active market (e.g. derivatives in connection<br />

with Modified Coinsurance/Coinsurance Funds Withheld treaties), are determined using<br />

appropriate measurem<strong>en</strong>t methods. In this regard, please see our remarks on the determination<br />

of fair values as well as the applicability criteria for determination of the need to take impairm<strong>en</strong>ts<br />

on certain financial instrum<strong>en</strong>ts in the subsection <strong>en</strong>titled “Investm<strong>en</strong>ts including income and<br />

exp<strong>en</strong>ses.” The allocation of financial instrum<strong>en</strong>ts to the various levels of the fair value hierarchy is<br />

described under item 11 of the Notes “Fair value hierarchy.” To the ext<strong>en</strong>t that significant measurem<strong>en</strong>t<br />

parameters are not based on observable market data (level 3), estimates and assumptions play<br />

a major role in determining the fair value of these instrum<strong>en</strong>ts.<br />

Impairm<strong>en</strong>t test of goodwill (carrying amount as at 31 December <strong>2011</strong>: EUR 690 million): The Group<br />

tests for impairm<strong>en</strong>t of goodwill in the manner described in the subsection <strong>en</strong>titled “Goodwill.”<br />

Insofar as the recoverable amount is based on calculations of the value in use, appropriate assumptions<br />

– such as sustainably achievable results and growth rates – are used as a basis (cf. item 1 of the<br />

Notes “Goodwill,” pages 209 et seq.).<br />

Deferred acquisition costs: At the balance sheet date, the Group recognised acquisition costs in the<br />

amount of EUR 4,013 million. The actuarial bases for amortisation of the deferred acquisition costs<br />

are continuously reviewed and adjusted where necessary. Impairm<strong>en</strong>t tests are carried out through<br />

regular checks on, for example, profit developm<strong>en</strong>ts, lapse assumptions and default probabilities.<br />

Pres<strong>en</strong>t value of future profits (pvfp) on acquired insurance portfolios: The PVFP (EUR 1,333 million<br />

as at 31 December <strong>2011</strong>) is the pres<strong>en</strong>t value of the expected future net cash flows from existing life<br />

insurance contracts at the time of acquisition, and is determined using actuarial methods. Uncertainties<br />

may arise with regard to the expected amount of these net cash flows.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!